إعلان
إعلان

ARGX

ARGX logo

argenx SE - ADR

837.43
USD
برعاية
-0.47
-0.06%
٣١ ديسمبر, ١٠:٥٦ UTC -5
مفتوح

تقارير أرباح ARGX

النسبة الإيجابية المفاجئة

ARGX تفوق 21 من 39 آخر التقديرات.

54%

التقرير التالي

بيانات التقرير القادم
٢٦ فبراير ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$1.31B
/
$6.41
التغير الضمني من Q3 25 (Revenue/ EPS)
+13.41%
/
+23.75%
التغير الضمني من Q4 24 (Revenue/ EPS)
+71.53%
/
+589.25%

argenx SE - ADR earnings per share and revenue

On ٣٠ أكتوبر ٢٠٢٥, ARGX reported earnings of 5.18 USD per share (EPS) for Q3 25, beating the estimate of 4.36 USD, resulting in a 18.63% surprise. Revenue reached 1.15 مليار, compared to an expected 1.08 مليار, with a 6.87% difference. The market reacted with a -0.20% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 18 analysts forecast an EPS of 6.41 USD, with revenue projected to reach 1.31 مليار USD, implying an increase of 23.75% EPS, and increase of 13.41% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
enGene Holdings Inc. Common Stock
Report Date
٢٢ ديسمبر ٢٠٢٥ For ربع سنوي4 25
Estimate
-$0.57
الفعلي
-$0.73
مفاجئة
-25.95%
logo
Outlook Therapeutics, Inc. Common Stock
Report Date
١٩ ديسمبر ٢٠٢٥ For ربع سنوي4 25
Estimate
-$0.25
الفعلي
-$0.19
مفاجئة
+26.47%
logo
Citius Oncology, Inc. Common Stock
Report Date
٢٣ ديسمبر ٢٠٢٥ For ربع سنوي4 25
Estimate
-$0.12
الفعلي
-$0.06
مفاجئة
+50.98%
الأسئلة الشائعة
For Q3 2025, argenx SE - ADR reported EPS of $5.18, beating estimates by 18.63%, and revenue of $1.15B, 6.87% above expectations.
The stock price moved down -0.2%, changed from $821.97 before the earnings release to $820.36 the day after.
The next earning report is scheduled for ٢٦ فبراير ٢٠٢٦.
Based on 18 analysts, argenx SE - ADR is expected to report EPS of $6.41 and revenue of $1.31B for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان